| Tevimbra (tislelizumab-jsgr) / BeiGene |
NCT05687357: Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma |
|
|
| Recruiting | 2b | 140 | RoW | Tislelizumab, S-1, Oxaliplatin, Nab paclitaxel, Radiation | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer, Gastroesophageal-junction Cancer | 02/27 | 08/27 | | |
ACTRN12622000207718p: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma |
|
|
| Not yet recruiting | 2 | 35 | | | Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG) | Hodgkin Lymphoma | | | | |
ACTRN12621000273886: Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer |
|
|
| Recruiting | 2 | 135 | | | The University of Sydney, Australian Government - Medical Research Future Fund (MRFF) | Endometrial Cancer | | | | |
ACTRN12622000207718: A study of a chemotherapy regime and tislelizumab in elderly patients with Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 35 | | | Australasian Leukaemia and Lymphoma Group , Australasian Leukaemia and Lymphoma Group (ALLG) | Hodgkin Lymphoma | | | | |
ChiCTR2100054451: Phase II clinical study of tislelizumab combined with R-CHOP in the first-line treatment of unspecified EBV-positive diffuse large B-cell lymphoma |
|
|
| Recruiting | 2 | 26 | China | Tislelizumab combined with R-CHOP | Fudan University Cancer Hospital ; Fudan University Cancer Hospital, BeiGene | EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) | | | | |
| Completed | 2 | 54 | RoW | Tislelizumab, BGB-A317, Paclitaxel, Gemcitabine, Etoposide, Pemetrexed, Cisplatin, Carboplatin | BeiGene | Locally Advanced Lung Cancer; Metastatic Lung Cancer | 02/19 | 12/20 | | |
BGB-A317-205, NCT03469557: BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma |
|
|
| Completed | 2 | 30 | RoW | Tislelizumab, BGB-A317, Cisplatin, 5-FU, Oxaliplatin, Capecitabine | BeiGene | Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma | 03/19 | 08/20 | | |
|
| Completed | 2 | 113 | RoW | Tislelizumab, BGB-A317 | BeiGene | Locally Advanced or Metastatic Urothelial Bladder Cancer | 09/19 | 03/21 | | |
|
|
2018-002492-17: Evaluation of a Treatment with tislelizumab and zanubrutinib in patients with a Richter Transformation. Bewertung einer Behandlung mit Tislelizumab und Zanubrutinib bei Patienten mit einer Richter-Transformation. |
|
|
| Not yet recruiting | 2 | 48 | Europe | Tislelizumab, Zanubrutinib, BGB-A317, BGB-3111, Concentrate and solvent for concentrate for solution for infusion, Capsule, Tislelizumab, Zanubrutinib | Universität zu Köln, BeiGene Ltd. | Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy, Patients with previously untreated Richter Transformation or patients who responded to up to one prior line of RT therapy, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 70 | RoW | Tislelizumab, BGB-A317 | BeiGene | Classical Hodgkin Lymphoma | 11/20 | 11/20 | | |
|
|
|
|
|
| Completed | 2 | 33 | RoW | Apatinib Combined With Tislelizumab and Chemotherapy, Combined therapy | Renmin Hospital of Wuhan University | Advanced Gastric Adenocarcinoma | 03/23 | 01/24 | | |
NCT04310943: Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma |
|
|
| Completed | 2 | 24 | RoW | Tislelizumab, Albumin paclitaxel, Bevacizumab | Zhou Chengzhi | Lung Adenocarcinoma Stage IV | 06/23 | 12/23 | | |
| Completed | 2 | 77 | Europe, Canada, RoW | Tislelizumab, BGB-A317 | BeiGene | Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma | 04/21 | 04/21 | | |
|
| Completed | 2 | 249 | Europe, RoW | Tislelizumab, BGB-A317 | BeiGene | Hepatocellular Carcinoma (HCC) | 06/21 | 07/22 | | |
NCT04541277: Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy |
|
|
| Recruiting | 2 | 55 | RoW | Tislelizumab, Decitabine, Azacitidine, Cytarabine, Idarubicin, Aclarithromycin, Recombinant Human Granulocyte Colony Stimulating Factor, Pegylated Recombinant Human Granulocyte Colony Stimulating Factor | Chinese PLA General Hospital | Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease | 08/21 | 08/22 | | |
ChiCTR2000040139: A prospective study of the efficacy and safety of tislelizumab combined with regorafenib in patients with unresectable or recurring cholangiocarcinoma after resection |
|
|
| Not yet recruiting | 2 | 42 | China | regorafenib + tislelizumab | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology ; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Beijing Association of Cancer Prevention and Treatment | Cholangiocarcinoma | | | | |
NCT04498793: Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 55 | RoW | Tislelizumab, Nab paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, First Affiliated Hospital Xi'an Jiaotong University, Wuhan Union Hospital, China, Beijing Huanxing Cancer Hospital | HER2-negative Breast Cancer | 12/21 | 12/22 | | |
NCT04866836: A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors |
|
|
| Recruiting | 2 | 20 | RoW | Radiotherapy, PD-1 monoclonal antibody | The First Affiliated Hospital with Nanjing Medical University | Cholangiocarcinoma | 12/21 | 10/22 | | |
| Active, not recruiting | 2 | 33 | RoW | tislelizumab, Albumin Paclitaxel, Carboplatin/Cisplatin | West China Hospital | Stage III, Non-small Cell Lung Cancer | 12/21 | 06/22 | | |
ChiCTR2100046698: Low-dose nab-paclitaxel plus tislelizumab in elderly patients with previously treated advanced non-small cell lung cancer |
|
|
| Recruiting | 2 | 30 | China | low-dose nab-paclitaxel plus tislelizumab | Changzhou Second People's Hospital ; Changzhou Second People’s Hospital, Chinese Society of Clinical Oncology-Shiyao, BeiGene Biotechnology Co., Ltd. | non-small cell lung cancer | | | | |
NCT04890392: Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC |
|
|
| Recruiting | 2 | 20 | RoW | PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin) | Wuhan Union Hospital, China | Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma | 01/22 | 02/22 | | |
NCT04539444: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | 2 | 10 | RoW | CD19/22 CART, Tislelizumab, PD-1 inhibitor | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 02/22 | 02/23 | | |
TREND, ChiCTR2000035262: Neoadjuvant Phase II Study of Tislelizumab combined with chemotherapy in Triple Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 65 | China | Tislelizumab | Liaoning Province Cancer Hospital ; Liaoning Province Cancer Hospital, BeiGene Shenzhou (Beijing) Biotechnology Co., Ltd. | Breast cancer | | | | |
| Recruiting | 2 | 120 | RoW | Tislelizumab, BGB-A317, Carboplatin, Pemetrexed, Bevacizumab, Nab paclitaxel | Shanghai Chest Hospital | Non Small Cell Lung Cancer | 04/22 | 03/25 | | |
FRONT-2, NCT06232759: TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma |
|
|
| Completed | 2 | 56 | RoW | Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab | Guangxi Medical University | Hepatocellular Carcinoma | 10/23 | 01/24 | | |
ChiCTR2000041542: Phase II study of Chidamide and Tislelizumab in advanced non-small cell lung cancer |
|
|
| Recruiting | 2 | 76 | China | Chidamide+Tislelizumab（±chemotherapy） | The General Hospital of the People's Liberation Army (PLAGH) ; The General Hospital of the People's Liberation Army (PLAGH), scientific research project | Non-small cell lung cancer | | | | |
ChiCTR2000041541: Phase II study of Chidamide and Tislelizumab in advanced Urothelial carcinoma |
|
|
| Recruiting | 2 | 20 | China | Chidamide plus Tislelizumab and chemotherapy | The General Hospital of the People's Liberation Army (PLAGH) ; The General Hospital of the People's Liberation Army (PLAGH), scientific research project | Urothelial carcinoma | | | | |
NCT04850157: Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT |
|
|
| Not yet recruiting | 2 | 30 | RoW | Tislelizumab, IMRT | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 04/22 | 12/23 | | |
NCT04834986: Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Tislelizumab combined with Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | Resectable Hepatocellular Carcinoma | 04/22 | 04/24 | | |
ChiCTR2100046039: Efficacy and safety of Tislelizumab combined with platinum-based chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC): a single-arm, open-lable, phase 2 study |
|
|
| Recruiting | 2 | 26 | China | Tislelizumab combined with platinum-based chemotherapy | Cancer Center, Sun Yat-Sen University ; Sun Yat-sen University Cancer Center, BeiGene (Beijing) Biotechnology Co., Ltd. | Prostate cancer | | | | |
2021-001075-17: Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Ociperlimab con Tislelizumab y quimioterapia en pacientes con cáncer de pulmón no microcítico no tratado |
|
|
| Not yet recruiting | 2 | 270 | Europe | Tislelizumab, Ociperlimab, BGB-A317, BGB-A1217, Concentrate for solution for infusion | BeiGene, Ltd., BeiGene, Ltd. | Metastatic non-small cell lung cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM) metastásico, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04] | | | | |
NCT04672317: Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma |
|
|
| Active, not recruiting | 2 | 20 | RoW | Immunotherapy combined with chemotherapy | RenJi Hospital | Neoadjuvant Therapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma | 06/22 | 06/22 | | |
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study |
|
|
| Not yet recruiting | 2 | 265 | RoW | Eribulin, Tislelizumab | Fudan University | Triple Negative Breast Cancer | 06/22 | 06/23 | | |
AdvanTIG-202, NCT04693234 / 2020-004657-77: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer |
|
|
| Completed | 2 | 178 | Europe, RoW | Tislelizumab, Ociperlimab, BGB-A1217 | BeiGene | Cervical Cancer | 06/22 | 08/23 | | |
| Recruiting | 2 | 52 | RoW | PD-1 inhibitor, PARP inhibitor | Tianjin Medical University Cancer Institute and Hospital | Lung Cancer | 06/22 | 04/25 | | |
ChiCTR2000033793: A single-arm exploratory clinical study of tirelizumab combined with anlotinib in the treatment of refractory small cell lung cancer after first-line platinum-based chemotherapy |
|
|
| Not yet recruiting | 2 | 30 | China | Tirelizumab combined with antinib | Fujian Province Cancer Hospital ; Fujian Province Cancer Hospital, None | SCLC | | | | |
NCT04672330: Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma |
|
|
| Completed | 2 | 16 | RoW | Tislelizumab, anti-PD-1 monoclonal antibody | RenJi Hospital | Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma | 01/23 | 11/23 | | |
ChiCTR2000041490: A single-arm, open-label, phase 2 clinical trial of Tislelizumab combined with Lucitanib for secondary hemophagocytic lymphohistiocytosis. |
|
|
| Recruiting | 2 | 29 | China | Baizean (tislelizumab) - BeiGene, Novartis, lucitanib (E 3810) - Clovis, Servier | Institute of Hematology & Hospital of Blood DiseasesChinese Academy of Medical Sciences & Peking Union Medical College | Hemophagocytic lymphohistiocytosis;Oncoogy | | | | |
LungMark, NCT05244837: Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC |
|
|
| Recruiting | 2 | 100 | RoW | Tislelizumab 200 mg, Tislelizumab, Carboplatin AUC 5, Carboplatin, pemetrexed 500mg/m2, pemetrexed, Paclitaxel 175mg/m2, Paclitaxel, Nab-paclitaxel 260 mg/m2, Nab-paclitaxel | Hao Long | Tislelizumab, Safety, Biomarker, Chemotherapy | 07/22 | 12/23 | | |
NCT05036798: Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System. |
|
|
| Active, not recruiting | 2 | 30 | RoW | Tislelizumab, Lenvatinib, Gemox | Tianjin Medical University Cancer Institute and Hospital | Potentially Resectable Locally Advanced Malignant Tumors of Biliary System | 07/22 | 12/23 | | |
NCT05050630: Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL |
|
|
| Recruiting | 2 | 73 | RoW | TR2-ICE | Affiliated Hospital to Academy of Military Medical Sciences, Beijing Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed, At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma, ECOG Physical Status Score is 0-3, The Researchers Judged That Life Expectancy Was at Least Three Months, Understand and Voluntarily Sign Written Informed Consent | 07/22 | 07/23 | | |
NeoATCT, NCT04914390: A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 32 | RoW | AT regimen, Anthracycline/Nab-paclitaxel, Tislelizumab, BGB-A317, Anlotinib, AL3818 | Sichuan Provincial People's Hospital | Triple-negative Breast Cancer | 03/25 | 09/25 | | |
NCT04989855: Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score |
|
|
| Not yet recruiting | 2 | 48 | RoW | Fruquintinib plus Tislelizumab | Sun Yat-sen University | Locally Advanced Rectal Cancer | 08/22 | 02/24 | | |
NCT05469061: Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC |
|
|
| Recruiting | 2 | 17 | RoW | Tislelizumab, 5-FU, cis Platinum | The First Affiliated Hospital with Nanjing Medical University | Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma | 08/22 | 11/22 | | |
TACT, NCT05024266: Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab, Albumin Paclitaxel, Carboplatin | First Affiliated Hospital of Zhejiang University | Lung Squamous Cell Carcinoma, Neoadjuvant Therapy, Immunotherapy | 08/22 | 08/23 | | |
2021-002474-99: Sitravatinib and Tislelizumab with Metastatic UVEAL Melanoma with Liver Metastases Sitravatinib y Tislelizumab en Melanoma UVEAL metastásico con metástasis hepáticas |
|
|
| Not yet recruiting | 2 | 34 | Europe | Tislelizumab, Sitravatinib (malate formulation), Injection/infusion, Capsule | Grupo Español Multidisciplinar de Melanoma (GEM), Mirati, Beigene | Metastatic Uveal Melanoma with liver metastases Melanoma uveal metastásico con metástasis hepáticas, Metastatic Uveal Melanoma with liver metastases Melanoma uveal metastásico con metástasis hepáticas, Diseases [C] - Cancer [C04] | | | | |
QLYY-iCCA-01, NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | HAIC+TAE, Tislelizumab, Surufatinib | Qilu Hospital of Shandong University, BeiGene | Intrahepatic Cholangiocarcinoma | 05/24 | 12/25 | | |
NCT04562311: Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | Chidamide with tislelizumab | Sun Yat-sen University | Bladder Cancer Stage IV | 09/22 | 09/23 | | |
NCT05149170: Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL |
|
|
| Recruiting | 2 | 30 | RoW | Anti-PD-1 monoclonal antibody, radiotherapy | Chinese Academy of Medical Sciences, Beijing Cancer Hospital, First Affiliated Hospital of Jilin University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type | 09/22 | 09/24 | | |
NCT05254899: Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL |
|
|
| Recruiting | 2 | 54 | RoW | Anti-PD-1 monoclonal antibody, Tislelizumab, Pegaspargase, Gemcitabine, Oxaliplatin, Involved site radiotherapy | Chinese Academy of Medical Sciences, Beijing Cancer Hospital, The Affiliated Hospital Of Guizhou Medical University, First Affiliated Hospital of Jilin University | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer | 09/22 | 09/24 | | |
NCT04599777: TACE Combined With Sorafenib and Tislelizumab for Advanced HCC |
|
|
| Completed | 2 | 30 | RoW | TACE combined with sorafenib and tislelizumab | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma Non-resectable | 10/22 | 10/22 | | |
RETICULA-NPC, NCT04921995: Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab | Fudan University | Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy, Stereotactic Body Radiation Therapy (SBRT) | 10/22 | 06/24 | | |
BGB-900-2001-IIT, NCT04734262: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) |
|
|
| Active, not recruiting | 2 | 98 | RoW | Sitravatinib, MGCD516, Tislelizumab, BGB-A317, Nab-paclitaxel, Nanoparticle albumin-bound paclitaxel | Fudan University | Metastatic Breast Cancer | 06/24 | 06/24 | | |
ChiCTR2000039389: Neoadjuvant chemotherapy and Tilelizumab in stage III (cTNM-IIIA.IIIB) non-small-cell lung cancer: an open-label, single-arm, phase II trial |
|
|
| Recruiting | 2 | 37 | | Neoadjuvant chemotherapy and Tilelizumab | West China Hospital, Sichuan University; West China Hospital Sichuan University, Donate by association | non-small-cell lung cancer | | | | |
ChiCTR2000039464: Tlislelizumab Plus Chidamide as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) |
|
|
| Recruiting | 2 | 25 | China | Tislelizumab + Chidamide | Chinese PLA General Hospital ; Chinese PLA General Hospital, Beigene.co.,ltd + chipscreen | Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) | | | | |
| Recruiting | 2 | 72 | RoW | Tislelizumab in combination with cTACE, BGB-A317 | Zhongda Hospital | Hepatocellular Carcinoma | 11/22 | 11/23 | | |
2020-003108-15: Testing immunotherapy for patients with liver cancer and moderately-altered liver functions Etude d’une immunothérapie chez des patients atteints de cancer du foie avec des fonctions hépatiques modérément altérées |
|
|
| Not yet recruiting | 2 | 50 | Europe | Tislelizumab, BGB-A317, Concentrate for solution for infusion | UNICANCER, BeiGene Switzerland GmbH | Hepatocellular Carcinoma (HCC), Child-Pugh B, ALBI grade 1 or 2 liver function, Liver cancer with moderately-altered liver functions, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 36 | RoW | Tislelizumab, Carboplatin, Pemetrexed | Sun Yat-sen University | NSCLC Stage IV, Brain Metastases, PD-1 Antibody | 11/22 | 01/23 | | |
RATIONALE-211, NCT04401800: Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma |
|
|
| Completed | 2 | 64 | RoW | Lenvatinib, Tislelizumab | BeiGene | Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 12/22 | 02/24 | | |
ChiCTR2100044313: A single-arm, prospective, multi-center phase II clinical study of tislelizumab injection combined with R-CHOP in the treatment of primary mediastinal large B-cell lymphoma |
|
|
| Recruiting | 2 | 20 | China | tislelizumab injection combined with R-CHOP | Affiliated Tumor Hospital of Xinjiang Medical University ; Affiliated Tumor Hospital of Xinjiang Medical University, BeiGene (Shanghai) bio-pharmaceutical Co. , Ltd. | Primary mediastinal Large B-Cell Lymphoma. | | | | |
NCT04911517: Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC. |
|
|
| Recruiting | 2 | 50 | RoW | long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations | Beijing Friendship Hospital, Hangzhou New Horizon Health Technology Co., Ltd., Beigene (Beijing) Biotechnology Co., Ltd, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Tianjin Medical University General Hospital, People's Hospital of Tianjin, Tianjin Medical University Cancer Institute & Hospital | Colorectal Neoplasms | 12/22 | 12/24 | | |
FRUIT, NCT04924179: Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC |
|
|
| Active, not recruiting | 2 | 25 | RoW | Tislelizumab plus Fruquintinib and SBRT | Huazhong University of Science and Technology | Patients With Advanced Metastatic Colorectal Cancer | 12/22 | 06/24 | | |
NCT05254847: Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC |
|
|
| Recruiting | 2 | 75 | RoW | Capecitabine combined with lenvatinib and tislelizumab | Fudan University | Biliary Tract Cancer | 12/22 | 12/24 | | |
NCT05380271: Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 60 | NA | sequential DEB-BACE and Arotinib and Tirelizumab, DEB-BACE alone | Gang Wu | Carcinoma, Non-Small Cell Lung | 12/22 | 12/25 | | |
| Active, not recruiting | 2 | 46 | Europe, US, RoW | Tislelizumab, BGB-A317 | BeiGene, Lymphoma Study Association | Classical Hodgkin Lymphoma | 12/22 | 09/24 | | |
NCT05143099: Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC |
|
|
| Active, not recruiting | 2 | 35 | RoW | TEC | Shanghai Zhongshan Hospital | Colorectal Neoplasms | 12/22 | 02/24 | | |
NCT05207904: Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases |
|
|
| Recruiting | 2 | 41 | RoW | Tislelizumab, paclitaxel, Carboplatin | Sun Yat-sen University | Non-Small Cell Squamous Lung Cancer, Brain Metastases | 12/22 | 06/23 | | |
NCT04620837: Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, Anlotinib hydrochloride, Anlotinib | Chinese Academy of Medical Sciences | Small Cell Lung Carcinoma | 12/22 | 12/23 | | |
NCT04924413: L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma |
|
|
| Not yet recruiting | 2 | 30 | NA | Tislelizumab, L-TIL | Quanli Gao | Malignant Melanoma | 12/22 | 12/25 | | |
RIFLE, NCT04948034: The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 68 | RoW | Stereotactic Ablative Radiotherapy (SABR), Fruquintinib, Tislelizumab | Fudan University | Metastatic Colorectal Cancer | 12/22 | 12/23 | | |
ChiCTR2100053182: Phase II exploratory study of radiotherapy combined with tislelizumab in the treatment of locally advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 2 | 30 | China | Radiotherapy combined with tislelizumab | Binzhou Medical University Hospital ; Binzhou Medical University Hospital, enterprise | Esophageal squamous cell carcinoma | | | | |
ChiCTR2200056854: Efficacy and safety of anlotinib combined with tirelizumab in mss colorectal cancer with multiline recurrence or no response: a randomized, controlled, multicenter study |
|
|
| Recruiting | 2 | 115 | China | Treated with anlotinib ;Treated with anlotinib in combination with tislelizumab | Army Medical Center of PLA ; Army Medical Center of PLA, Key program of clinical technology innovation of Army Medical University | Colorectal cancer | | | | |
NCT04705129: Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL |
|
|
| Recruiting | 2 | 40 | RoW | Zanubrutinib, Tislelizumab | Ruijin Hospital | Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos | 01/23 | 01/24 | | |
NCT04777162: Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab, Anlotinib | Peking University | Gastric Cancer, Colo-rectal Cancer | 01/23 | 05/23 | | |
NCT04799548: A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma |
|
|
| Recruiting | 2 | 71 | RoW | Transcatheter Arterial Chemoembolization, Tislelizumab | Shanghai Zhongshan Hospital | Advanced Gastric Cancer | 12/24 | 01/26 | | |
NCT06235918: Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab, BGB-A317, Nab-paclitaxel, Carboplatin | Xiang Lu | Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma | 01/25 | 01/26 | | |
ZSAB-TOP, NCT05023109: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC |
|
|
| Active, not recruiting | 2 | 45 | RoW | GP+PD-1+Tight | Shanghai Zhongshan Hospital, Jining Medical University, Cancer Hospital of Guangxi Medical University | Biliary Tract Carcinoma | 01/23 | 12/24 | | |
AdvanTIG-203, NCT04732494 / 2020-004658-32: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Completed | 2 | 125 | Europe, RoW | Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Placebo, Ociperlimab placebo | BeiGene | Esophageal Squamous Cell Carcinoma | 02/23 | 12/23 | | |
| Active, not recruiting | 2 | 30 | RoW | Tislelizumab | Wuhan Union Hospital, China, BeiGene | Esophagus Cancer, Neoadjuvant Therapy | 03/23 | 12/24 | | |
NCT05314101: TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, bevacizumab, TAS-102 | Fujian Cancer Hospital | Immunotherapy, Colorectal Cancer | 02/23 | 02/24 | | |
| Withdrawn | 2 | 0 | US | Intravenous Tislelizumab, immunotherapy, Chemotherapy, carboplatin and paclitaxel, Fractionated radiation, Esophagectomy | Zhonglin Hao, BeiGene, University of Kentucky | Esophageal Cancer, Esophagogastric Junction Cancer | 03/23 | 12/33 | | |
NCT04899427: Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma |
|
|
| Recruiting | 2 | 32 | RoW | orelabrutinib, Sintilimab, Tislelizumab | Peking Union Medical College Hospital, Beijing Hospital, Beijing Tongren Hospital, Beijing Luhe Hospital, Shanxi Province Renmin Hospital, Henan Cancer Hospital, Henan Province Renmin Hospital, The Second Affiliated Hospital of Dalian Medical University, The Forth Hospital of Hebei Medical University, The First Hospital of Chinese Medical University, Qilu Hospital of Shandong University, The First Hospital of Zhengzhou University | Primary Central Nervous System Lymphoma | 03/23 | 10/23 | | |
NCT05310383: Tislelizumab and Radiotherapy for Recurrent Cervical Cancer |
|
|
| Recruiting | 2 | 58 | RoW | Tislelizumab plus radiotherapy | Lei Li | Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma, Radiotherapy, Immunotherapy, Anti-programmed Cell Death Receptor 1, Immune Checkpoint Inhibitors, Tislelizumab, Objective Response Rate, Survival Outcomes | 03/23 | 03/24 | | |
NCT05291052: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, Lenvatinib, Oxaliplatin, Capecitabine | The First Affiliated Hospital with Nanjing Medical University | Biliary Tract Tumor | 03/23 | 03/24 | | |
NCT05634564: Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 62 | RoW | Tislelizumab, Gemcitabine, Nab paclitaxel, Hypofractionated radiotherapy with simultaneous integrated boost | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Carcinoma | 04/23 | 12/23 | | |
NCT04814069: A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study |
|
|
| Not yet recruiting | 2 | 38 | NA | Tislelizumab | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Head and Neck Cancer, Radiation, PD-1 | 04/23 | 12/23 | | |
NCT04815408: PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer |
|
|
| Recruiting | 2 | 40 | RoW | BGB-A317, albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Ovarian Cancer, Neoadjuvant Chemotherapy, Anti-PD-1, Neoadjuvant Immunotherapy | 04/23 | 04/25 | | |
NCT05375734: Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab in combination with anlotinib | Second Affiliated Hospital of Nanchang University | Pulmonary Pleomorphic Carcinoma, Immunotherapy, Tislelizumab | 04/23 | 12/24 | | |
NCT05299476: CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA |
|
|
| Recruiting | 2 | 30 | RoW | CAPOX combined with bevacizumab and Tislelizumab | Chinese PLA General Hospital | Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5 | 12/24 | 06/25 | | |
| Active, not recruiting | 2 | 70 | RoW | Tislelizumab, BGB-A317 | BeiGene | Resectable Esophageal Squamous Cell Carcinoma | 04/23 | 05/26 | | |
TAOS-3B, NCT05223088: Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab, Apatinib Mesylate, oxaliplatin, Tegafur | Fujian Cancer Hospital | Immunotherapy, Gastrict Cancer | 04/23 | 04/24 | | |
NCT04843267: A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab | Sun Yat-sen University | Hodgkin Lymphoma, Chemotherapy Effect | 05/23 | 05/25 | | |
NCT05290116: HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 17 | RoW | HAIC Combined with Tislelizumab and Apatinib | Yunfei Yuan | Intrahepatic Cholangiocarcinoma | 05/23 | 09/23 | | |
| Recruiting | 2 | 53 | RoW | Tislelizumab, Oxaliplatin, S-1, Capecitabine | Sun Yat-sen University | Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach | 11/24 | 11/27 | | |
NCT04899414: Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma |
|
|
| Not yet recruiting | 2 | 50 | RoW | Dexamethasone, azacytidine, Pegaspargase, Tislelizumab | Peking University, Beijing Cancer Hospital | NK/T Cell Lymphoma | 05/23 | 10/23 | | |
NCT05844371: Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery |
|
|
| Recruiting | 2 | 60 | RoW | tirelizumab, chemotherapy with oxaliplatin + heroda | Yixing People's Hospital | Gastric Cancer | 06/23 | 04/24 | | |
ITTACC, NCT05614453: Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy |
|
|
| Withdrawn | 2 | 57 | NA | Tislelizumab, BGB-A317, Sitravatinib, MGCD516 | Australia New Zealand Gynaecological Oncology Group, BeiGene | Metastatic Cervical Cancer | 06/23 | 06/23 | | |
NCT05058560: Tislelizumab in Addition to BACE in Patients With NSCLC |
|
|
| Active, not recruiting | 2 | 30 | RoW | Tislelizumab, Bronchial artery chemoembolization (BACE) | The First Affiliated Hospital of Zhengzhou University | NSCLC | 06/23 | 12/23 | | |
ChiCTR2200061305: Oncorine (H101) plus tislelizumab and platinum-based two-drug chemotherapy in previously untreated advanced non-small cell lung cancer, a phase II single-arm clinical trail |
|
|
| Not yet recruiting | 2 | 30 | | H101 | Fujian Cancer Hospital; Fujian Cancer Hospital, Self-financing | lung cancer | | | | |
SACTION01, NCT05319574: SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 46 | RoW | SBRT, stereotactic body radiation therapy, Tislelizumab | Sun Yat-sen University | Carcinoma, Non-Small-Cell Lung | 06/23 | 04/25 | | |
